The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of fixed dose-rate gemcitabine plus S-1 as second-line treatment in advanced biliary tract cancer.
 
Satoshi Kobayashi
Honoraria - AstraZeneca; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Novartis
 
Kazuya Sugimori
No Relationships to Disclose
 
Chigusa Morizane
Honoraria - Lilly; Novartis; Pfizer; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Novartis; Yakult Honsha
Research Funding - GlaxoSmithKline (Inst); Nobelpharma (Inst); Pfizer (Inst)
 
Yasushi Kojima
Speakers' Bureau - Chugai Pharma; Takeda
Research Funding - Kyowa Hakko Kirin (Inst)
 
Makoto Ueno
Honoraria - Abbott Laboratories; AstraZeneca; Boston Scientific; Kyowa Hakko Kirin; Lilly; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Manabu Morimoto
Honoraria - Bayer; Dainippon Sumitomo Pharma; Eisai; Nippon Kayaku
Research Funding - Bayer (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Shionogi (Inst); Yakult Honsha (Inst)
 
Shinichi Ohkawa
Honoraria - Lilly; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim